Budget Amount *help |
¥16,900,000 (Direct Cost: ¥13,000,000、Indirect Cost: ¥3,900,000)
Fiscal Year 2019: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2018: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2017: ¥7,670,000 (Direct Cost: ¥5,900,000、Indirect Cost: ¥1,770,000)
|
Outline of Final Research Achievements |
There has been no specific treatment for parechovirus-A3 (PeV-A3) infection, which causes severe infection in neonates and young infants. We evaluated the effectiveness of antimicrobials for PeV-A3 using in vitro models. As a results, we found inhibition effects of soem antimicrobials for PeV-A3. These medications could lead to the future treatment strategies for PeV-A3 infection.
|